A new World Health Organization (WHO) study published today in eBioMedicine names 17 pathogens that regularly cause diseases in communities as top priorities for new vaccine development.
Researchers at the World Health Organization have identified 17 pathogens most in need of new or improved vaccines, including threats like HIV, malaria, and influenza.
This update in the health sector highlights major developments including DiaSorin's significant profit growth, GSK's RSV ...
Heading into Moderna’s third-quarter earnings, investors and analysts will be watching to see how the Cambridge drugmaker ...
Fortunately, there is a safe, effective vaccine. For several years ... But in 2022, after the pandemic precautions relaxed, cases of influenza and RSV surged. Now it appears whooping cough is back as ...
Individuals 65-and-up, particularly those with other health conditions, are among those most-at-risk for severe cases of RSV.
GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...
Moderna sells two products — a vaccine for COVID and another for RSV. The company has struggled as the pandemic faded and its ...
Dr. Supha Arthurs, an infectious disease specialist with Sanford Health, joined Nicholas Quallich for episode 31 of The Voice ...
A fresh wave of disinformation about vaccines is flaring amid the 2024 campaign. The FDA's top vaccine official believes ...
Researchers sought to determine if the RSV vaccine leads to better health outcomes among older adults with IBD.
Preliminary data were announced from 2 clinical trials evaluating Arexvy in a broader population of adults at increased for RSV disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback